drugset
drugset / Trial / NCT07633197

A Phase I Clinical Trial of Recombinant Herpes Zoster Vaccine (CHO Cell)

NCT07633197 ↗

Phase 1 Enrolling by invitation 120 enrolled Changchun BCHT Biotechnology Co.
RandomizedParallel-groupDouble-blindPrevention

Summary

To evaluate the safety and tolerability of different dosages of recombinant zoster vaccine (CHO cell) when administered to adults aged 40 years and older.

Timeline

Start
2026-05-28
Primary completion
2026-12-28
Completion
2027-11-30

Drugs

EvaluationDrugModalityDoseRoute
Subject Recombinant Herpes Zoster Vaccine Vaccine 0.5 ml Intramuscular

Indications

viral infectious disease